BIOINVEST BREAKING NEWS – Viking (VKTX) Viking Therapeutics (VKTX) – Oral VK2735 Delivers Excellent Phase I Weight Loss of 5.3% at 28 Days; Highest Dose Not Reached Yet Due to Outstanding Safety. (…more)
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.